Theseus Pharmaceuticals, Inc. Common Stock
THRX
THRX was delisted on the 13th of February, 2024.
46 hedge funds and large institutions have $441M invested in Theseus Pharmaceuticals, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 46 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$254M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$82.3M |
| 3 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
+$48.5M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$19.6M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
+$13.5M |
Top Sellers
THRX Hedge Fund Activity: Q4 2021 in Review
46 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Theseus Pharmaceuticals, Inc. Common Stock (THRX) for Q4 2021, worth a combined $441M.
Buyers outnumbered sellers: 46 funds opened new THRX positions and 0 closed out — a net gain of 46 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $254M.
- 46 institutional investors held Theseus Pharmaceuticals, Inc. Common Stock (THRX) as of Q4 2021, up from 0 in Q3 2021.
- Funds reported $441M of Theseus Pharmaceuticals, Inc. Common Stock stock for Q4 2021.
- 46 funds opened new Theseus Pharmaceuticals, Inc. Common Stock positions in Q4 2021 and 0 closed out, a net change of +46 holders.
- The largest Theseus Pharmaceuticals, Inc. Common Stock buyer in Q4 2021 was OrbiMed, an estimated $254M added.
Based on aggregated 13F filings for Q4 2021.